On August 3rd, the National Pharmaceutical Council, a health policy research organization, announced MBBP client Shire plc as a new member. Dr. Jeffrey M. Jonas, Senior VP, Specialty Pharmaceuticals R&D, will serve as Shire’s representative on the NPC board of directors. In a recent press release, Dr. Jonas describes Shire’s view on the new membership:
Shire is very supportive of NPC’s focus on evidence-based medicine and on policy research related to comparative effectiveness research, pharmaceutical innovation and the value of medicines. We’re pleased to be a part of this organization and look forward to working with NPC on issues affecting the pharmaceutical industry.